GeNeuro SA bankrupt after the end of the composition moratorium

Geneva, Switzerland, January 28, 2026 – GeNeuro SA, a biopharmaceutical company listed on Euronext Paris, has filed for bankruptcy. The Geneva Court of First Instance refused to extend the final debt restructuring agreement granted on September 26, 2025. The company was unable to finalize any takeover or restructuring plan, despite its efforts to explore options such as recapitalization or negotiations with its creditors.

GeNeuro SA's programs, focused on diseases such as multiple sclerosis and long COVID, failed to ensure the company's long-term viability. Creditors will have priority over shareholders in receiving compensation. The Geneva Cantonal Bankruptcy Office is now handling the case.